Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study

Publisher： Karger

E-ISSN： 1423-0232|78|5-6|329-339

ISSN： 0030-2414

Source： Oncology, Vol.78, Iss.5-6, 2010-08, pp. : 329-339

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study

By  

Oncology, Vol. 83, Iss. 3, 2012-08 ,pp. : 151-157

Karger

Access to resources Recommend Favorite

An Open-Label Safety Study of First-Line Bevacizumab in Combination with Standard Chemotherapy in Chinese Patients with Metastatic Colorectal Cancer Treated in an Expanded Access Program in Taiwan

By  

Oncology, Vol. 84, Iss. 5, 2013-03 ,pp. : 299-304

Karger

Access to resources Recommend Favorite

Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer

By  

Oncology, Vol. 89, Iss. 3, 2015-05 ,pp. : 152-158

Karger

Access to resources Recommend Favorite

Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer

By  

Oncology Research and Treatment, Vol. 40, Iss. 1-2, 2017-01 ,pp. : 21-26

Karger

Access to resources Recommend Favorite

Genetic Polymorphisms of FcγRIIa and FcγRIIIa Are Not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 83-89

Karger

Access to resources Recommend Favorite